A narrative review of therapies for scalp dermatomyositis.
alopecia
dermatomyositis
scalp
scalp dermatomyositis
treatments
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
08
09
2021
received:
08
06
2021
accepted:
19
09
2021
pubmed:
23
9
2021
medline:
2
4
2022
entrez:
22
9
2021
Statut:
ppublish
Résumé
Cutaneous involvement of the scalp is a common manifestation of dermatomyositis (DM), occurring in up to 82% of adults with DM. Scalp DM predominantly affects women and is characterized by dermatitis, alopecia, pruritus, and/or burning. While cutaneous DM negatively impacts quality-of-life, scalp symptoms in particular are often severe, debilitating, and recalcitrant to standard DM therapies. Currently, there is a paucity of guidelines to inform management of scalp symptoms in patients with cutaneous DM. In this narrative review, we summarize the treatments utilized to manage scalp DM and highlight potential areas for future research. We identified eight studies that reported on 27 treatments focused on cutaneous DM and described outcomes on scalp symptoms. A majority of the treatments were standard therapies for cutaneous DM and resulted in no or minimal improvement in scalp symptoms. Five therapies did result in complete resolution of scalp symptoms and were recommended as potential areas of future research. These included low-dose naltrexone and platelet-rich plasma, as well as two frequent and one less common therapy for cutaneous DM respectively: intravenous immunoglobulin, rituximab, and apremilast. Though the literature was not systematically assessed in this review, these findings illustrate not only that strategies for refractory scalp DM are lacking, but also that those demonstrating potential efficacy are limited by low levels of evidence. Additional studies, especially randomized controlled trials, are needed to better inform management of scalp DM.
Substances chimiques
Immunoglobulins, Intravenous
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15138Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Alves F, Gonçalo M. Suspected inflammatory rheumatic diseases in patients presenting with skin rashes. Best Pract Res Clin Rheumatol. 2019;33(4):101440.
Marvi U, Chung L, Fiorentino DF. Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol. 2012;57(5):375-381.
Kasteler JS, Callen JP. Scalp involvement in dermatomyositis: often overlooked or misdiagnosed. JAMA. 1994;272(24):1939-1941.
Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25-34.
Jasso-Olivares JC, Tosti A, Miteva M, Domínguez-Cherit J, Díaz-González JM. Clinical and dermoscopic features of the scalp in 31 patients with dermatomyositis. Skin Appendage Disord. 2017;3(3):119-124.
Tilstra JS, Prevost N, Khera P, English JC III. Scalp Dermatomyositis revisited. Arch Dermatol. 2009;145(9):1062-1063.
Peloro TM, Miller OF III, Hahn TF, Newman ED. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol. 2001;45(1):28-34.
Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387-408.
Concha JSS, Pena S, Gaffney RG, et al. Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. Br J Dermatol. 2020;182(2):410-417.
Iorizzo LJ, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008;59(1):99-112.
Goreshi R, Chock M, Foering K, et al. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011;65(6):1107-1116.
Choy EHS, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology. 2002;41(1):7-13.
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
Bitar C, Maghfour J, Ho-Pham H, Stumpf B, Boh E. Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case Rep. 2019;5(2):191-194.
Charlton D, Moghadam-Kia S, Smith K, Aggarwal R, English JC III, Oddis CV. Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast. J Clin Rheumatol. 2019.
Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56(1):148-153.
Manudhane AP, Schrom KP, Ezaldein HH, Armile JA. Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis. Dermatol Online J. 2019;25(6):11.
Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601-607.
Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology. 2017;56(2):247-254.
Hosking A, Juhász M, Ekelem C, et al. Improvement in scalp dermatomyositis with platelet-rich plasma. JOJ Dermatol Cosmet. 2018;1(3):45-48.
Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):344-347.
Fala L. Otezla (Apremilast), an Oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105-110.
Clinicaltrials.gov. A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients with Dermatomyositis. NIH; 2011. Accessed 2020. https://clinicaltrials.gov/ct2/show/NCT01140503
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-1590.
Tortelly VD, De Mattos T, Fernandes LSA, Nunes BEM, Melo DF. Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias? Dermatol Online J. 2019;25(8):12.
Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose naltrexone for lichen Planopilaris. J Drugs Dermatol. 2017;16(11):1140-1142.
Fujimoto JG, Pitris C, Boppart SA, Brezinski ME. Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. Neoplasia. 2000;2(1-2):9-25.
Shapiro J, Ho A, Sukhdeo K, Yin L, Lo SK. Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: a randomized controlled trial. J Am Acad Dermatol. 2020;83(5):1298-1303.
Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013;169(3):690-694.
Singh S. Role of platelet-rich plasma in chronic alopecia areata: our Centre experience. Indian J Plast Surg. 2015;48(1):57-59.
Alves R, Grimalt R. Platelet-rich plasma and its use for cicatricial and non-cicatricial Alopecias: a narrative review. Dermatol Ther. 2020;10(4):623-633.
Dina Y, Aguh C. Use of platelet-rich plasma in cicatricial alopecia. Dermatol Surg. 2019;45(7):979-981.
Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314-324.
Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32(5 Pt 1):754-757.
Galimberti F, Li Y, Fernandez AP. Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. J Am Acad Dermatol. 2015;73(1):174-176.